

Sheet 1 of 2

TECH CENTER 1600/2900

JUN 19 2002

RECEIVED

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50128/002003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. §1.98(b))		Serial No.	10/003,674
		Applicant	M. Michael Wolfe et al.
		Filing Date	October 23, 2001
		Group	1647
		IDS Filed	June 7, 2002
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
AR	Cleator and Gourlay, "Release of Immunoreactive Gastric Inhibitory Polypeptide (IR-GIP) by Oral Ingestion of Food Substance," <i>Am. J. Surg.</i> 130:128-135, 1975.		
	Dupre et al., "Stimulation of Insulin Secretion by Gastric Inhibitory Polypeptide in Man," <i>J. Clin. Endocrinol. Metab.</i> 37:826-828, 1973.		
	Gremlich et al., "Cloning, Functional Expression, and Chromosomal Localization of the Human Pancreatic Islet Glucose-Dependent Insulinotropic Polypeptide Receptor," <i>Diabetes</i> 44:1202-1208, 1995.		
	Jornvall et al., "Amino Acid Sequence and Heterogeneity of Gastric Inhibitory Polypeptide (GIP)," <i>FEBS Letters</i> 123:205-210, 1981.		
	Kieffer et al., "Glucose-Dependent Insulinotropic Polypeptide Stimulated Insulin Release from a Tumor-Derived Beta-Cell Line (Beta TC3)," <i>Can. J. Physiol. Pharmacol.</i> 71:917-922, 1993.		
	Kolligs et al., "Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9-39) Amide," <i>Diabetes</i> 44:16-19, 1995.		
	Kreymann et al., "Glucagon-Like Peptide-1 7-36: A Physiological Incretin in Man," <i>Lancet</i> 2:1300-1304, 1987.		
	Mojsov et al., "Insulinotropin: Glucagon-Like Peptide I (7-37) Co-Encoded in the Glucagon Gene is a Potent Stimulator of Insulin Release in the Perfused Rat Pancreas," <i>J. Clin. Invest.</i> 79:616-619, 1987.		
	Nauck et al., "Additive Insulinotropic Effects of Exogenous Synthetic Human Gastric Inhibitory Polypeptide and Glucagon-Like Peptide-1-(7-36) Amide Infused at Near-Physiological Insulinotropic Hormone and Glucose Concentrations," <i>J. Clin. Endocrinol. Metab.</i> 76:912-917, 1993.		
	Nauck et al., "Insulinotropic Properties of Synthetic Human Gastric Inhibitory Polypeptide in Man: Interactions with Glucose, Phenylalanine, and Cholecystokinin-8," <i>J. Clin. Endocrinol. Metab.</i> 69:654-662, 1989.		
	Nauck et al., "Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses," <i>J. Clin. Endocrinol. Metab.</i> 63:492-498, 1986.		
	Nauck et al., "Reduced Incretin Effect in Type 2 (Non-Insulin-Dependent) Diabetes," <i>Diabetologia</i> 29:46-52, 1986.		
	Orskov et al., "Radio-Immunoassays for Glucagon-Like Peptides 1 and 2 (GLP-1 and GLP-2)," <i>Scand. J. Clin. Lab. Invest.</i> 47:165-174, 1987.		
	Orskov et al., "Proglucagon Products in Plasma of Noninsulin-Dependent Diabetics and Nondiabetic Controls in the Fasting State and After Oral Glucose and Intravenous Arginine," <i>J. Clin. Invest.</i> 87:415-423, 1991.		
	Rossowski et al., "Reduced Gastric Acid Inhibitory Effect of a pGIP(1-30) NH2 Fragment with Potent Pancreatic Amylase Inhibitory Activity," <i>Regul. Pept.</i> 29:9-17, 1992.		
	Salera et al., "Circadian Rhythm of Gastric Inhibitory Polypeptide (GIP) in Man," <i>Metabolism</i> 32:21-24, 1983.		
AR	Schmid et al., "Comparison of GLP-1(7-36amide) and GIP on Release of Somatostatin-Like Immunoreactivity and Insulin from the Isolated Rat Pancreas," <i>Z. Gastroenterol.</i> 28:280-284, 1990.		

Daniel Rando

51214

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.